ABLX - Ablynx NV

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
52.87
+0.07 (+0.13%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close52.80
Open52.92
Bid0.00 x 3000
Ask0.00 x 1000
Day's Range52.80 - 53.15
52 Week Range17.75 - 55.29
Volume14,581
Avg. Volume62,053
Market Cap3.215B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.72
Trade prices are not sourced from all markets
  • Sanofi Focuses on Integrating Recently Acquired Ablynx
    Market Realist13 days ago

    Sanofi Focuses on Integrating Recently Acquired Ablynx

    On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19. The acquisition was one of two announced in January to advance its blood disorder portfolio. The other acquisition was of Bioverative.

  • What does Ablynx NV’s (EBR:ABLX) Balance Sheet Tell Us About Its Future?
    Simply Wall St.22 days ago

    What does Ablynx NV’s (EBR:ABLX) Balance Sheet Tell Us About Its Future?

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ablynx NV (EBR:ABLX), with a market cap of €3.38b, often get neglectedRead More...

  • Ablynx NV (EBR:ABLX): What Does The Future Look Like?
    Simply Wall St.28 days ago

    Ablynx NV (EBR:ABLX): What Does The Future Look Like?

    The most recent earnings release Ablynx NV’s (ENXTBR:ABLX) announced in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below, I’veRead More...

  • Are Ablynx NV’s (EBR:ABLX) Interest Costs Too High?
    Simply Wall St.last month

    Are Ablynx NV’s (EBR:ABLX) Interest Costs Too High?

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ablynx NV (ENXTBR:ABLX), with a market cap of €3.38B, often get neglectedRead More...

  • ACCESSWIRE2 months ago

    Wired News – Sanofi and Ablynx Announce Results of the Initial Tender Offer Period and Commencement of Squeeze-Out Tender Period

    LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free research report on Sanofi American Depositary Shares (NYSE: SNY) ("Sanofi"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SNY as the Company's latest news hit the wire. On May 14, 2018, the Company along with Ablynx NV (NASDAQ: ABLX) together reported the successful results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares, including shares represented by American Depositary Shares (ADSs), warrants, and convertible bonds of Ablynx.

  • Who Are The Major Shareholders Of Ablynx NV (EBR:ABLX)?
    Simply Wall St.3 months ago

    Who Are The Major Shareholders Of Ablynx NV (EBR:ABLX)?

    Today, I will be analyzing Ablynx NV’s (ENXTBR:ABLX) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its share performanceRead More...

  • How Ablynx NV (EBR:ABLX) Can Impact Your Portfolio Volatility
    Simply Wall St.3 months ago

    How Ablynx NV (EBR:ABLX) Can Impact Your Portfolio Volatility

    If you are a shareholder in Ablynx NV’s (ENXTBR:ABLX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • Market Exclusive4 months ago

    Here’s What’s Moving Protagonist And Ablynx Right Now

    Protagonist Therapeutics, Inc. (PTGX) is drawing a lot of attention in the biotechnology space at the moment on the back of the release of some data rooted in a clinical trial program set up to investigate an asset called PTG-100. Tahis is the lead asset from Protagonist’s development pipeline and, unfortunately for the company and […] The post Here’s What’s Moving Protagonist And Ablynx Right Now appeared first on Market Exclusive.

  • What Do Analysts Think About Ablynx NV’s (EBR:ABLX) Long Term Outlook?
    Simply Wall St.4 months ago

    What Do Analysts Think About Ablynx NV’s (EBR:ABLX) Long Term Outlook?

    Ablynx NV’s (ENXTBR:ABLX) announced its latest earnings update in December 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investors Today IRead More...

  • Does Ablynx NV’s (EBR:ABLX) Debt Level Pose A Problem?
    Simply Wall St.4 months ago

    Does Ablynx NV’s (EBR:ABLX) Debt Level Pose A Problem?

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ablynx NV (ENXTBR:ABLX) with a market-capitalization of €3.30B, rarely draw their attention. Despite this, the two otherRead More...

  • Sanofi (SNY) Q4 2017 Earnings Conference Call Transcript
    Motley Fool5 months ago

    Sanofi (SNY) Q4 2017 Earnings Conference Call Transcript

    SNY earnings call for the period ending December 31, 2017.

  • TheStreet.com6 months ago

    Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

    A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

  • Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx
    GuruFocus.com6 months ago

    Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx

    Drugmaker expands reach in blood disease space

  • TheStreet.com6 months ago

    5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

    U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

  • Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx
    Bloomberg6 months ago

    Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx

    Sanofi agreed to buy Belgium’s Ablynx NV for 3.9 billion euros ($4.8 billion), leapfrogging an unsolicited bid from the French drugmaker’s fierce rival, Novo Nordisk A/S, to gain a potential blockbuster ...

  • Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize
    Bloomberg6 months ago

    Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize

    It began almost three decades ago with a container of frozen camel blood in Belgium, took a detour through Morocco and progressed to a stock listing in New York last year. The latest chapter in Ablynx ...

  • Capital Cube8 months ago

    ETFs with exposure to Ablynx NV : November 21, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ablynx NV Here are 5 ETFs with the largest exposure to ABLX-US. Comparing the performance and risk of Ablynx NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Ablynx NV :ABLX-US: Earnings Analysis: For the six months ended June 30, 2017 : November 9, 2017
    Capital Cube8 months ago

    Ablynx NV :ABLX-US: Earnings Analysis: For the six months ended June 30, 2017 : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Ablynx NV reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Ablynx NV – Medivir AB Unsponsored ADR and MorphoSys AG Sponsored ADR (MVRBY-US and MPSYY-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 37.94 ... Read more (Read more...)

  • Sanofi Outbids Novo With $4.8B Ablynx Takeover 
    Bloomberg Video6 months ago

    Sanofi Outbids Novo With $4.8B Ablynx Takeover 

    Jan.29 -- Ablynx NV agreed to a takeover bid from Sanofi worth about $4.8 billion, snubbing a lower offer from Novo Nordisk A/S. Bloomberg’s Benedikt Kammel has more on "Bloomberg Markets."

  • Novo CFO Says Bid Intention Is for Dialogue With Ablynx
    Bloomberg Video6 months ago

    Novo CFO Says Bid Intention Is for Dialogue With Ablynx

    Jan.08 -- Jesper Brandgaard, chief financial officer at Novo Nordisk, discusses the company's unsolicited $3.1 billion bid for Ablynx NV. He speaks with Francine Lacqua on "Bloomberg Surveillance."